Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: DDAVP

« Back to Dashboard
Ddavp is a drug marketed by Ferring Pharms Inc and is included in three NDAs. It is available from two suppliers.

The generic ingredient in DDAVP is desmopressin acetate. There are eighteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

Summary for Tradename: DDAVP

Suppliers / Packagers: see list15

Clinical Trials for: DDAVP

DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty
Status: Not yet recruiting Condition: Postoperative Ecchymosis

Efficacy and Safety of IL-11 in DDAVP Unresponsive
Status: Completed Condition: Hemophilia A; Von Willebrand Disease

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
Status: Enrolling by invitation Condition: Hemophilia A

The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion
Status: Completed Condition: Gender Difference in V2 Receptor Function in Response to dDAVP Infusion; Nocturia; Nocturnal Enuresis

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept
Status: Completed Condition: Intracerebral Hemorrhage

1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy
Status: Completed Condition: Kidney Failure

Study of DDAVP Combined With TXA on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery
Status: Active, not recruiting Condition: Idiopathic Scoliosis

Desmopressin Response in the Young
Status: Completed Condition: Primary Nocturnal Enuresis

Effect of Aspirin, Hemodilution and Desmopressin on Platelet Dysfunction
Status: Completed Condition: Platelet Dysfunction; Hemodilution; Mild Hypothermia; NSAID; Desmopressin

Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery
Status: Completed Condition: Acquired Von Willebrand Disease Secondary to Severe Aortic Stenosis; Heye´s Syndrome; Severe Aortic Stenosis

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc
desmopressin acetate
INJECTABLE;INJECTION018938-001Mar 30, 1984RXYes<disabled><disabled>
Ferring Pharms Inc
desmopressin acetate
SPRAY, METERED;NASAL017922-003Aug 7, 1996RXYes<disabled><disabled>
Ferring Pharms Inc
desmopressin acetate
SPRAY, METERED;NASAL017922-002Feb 6, 1989DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn